Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes

Drug Metabolism and Disposition

Volumn 31, Issue 7, 2003, Pages 945-954

  Ito, Kiyomi ^a   Ogihara, Kanako ^a   Kanamitsu, Shin Ichi ^a   Itoh, Tomoo ^a  

^a KITASATO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; CYTOCHROME P450 3A; ERYTHROMYCIN; ETIZOLAM; FLUOROURACIL; MACROLIDE; MIDAZOLAM; SORIVUDINE; TRIAZOLAM;

AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG HYDROXYLATION; DRUG POTENCY; ENZYME INACTIVATION; ENZYME KINETICS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; PARAMETER; PREDICTION; PRIORITY JOURNAL; TIME;

ANTI-BACTERIAL AGENTS; ARYL HYDROCARBON HYDROXYLASES; AZITHROMYCIN; CLARITHROMYCIN; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; ERYTHROMYCIN; HUMANS; HYDROXYLATION; MACROLIDES; MICROSOMES, LIVER; MIDAZOLAM; MODELS, BIOLOGICAL; OXIDOREDUCTASES, N-DEMETHYLATING; TIME FACTORS;

STAPHYLOCOCCUS PHAGE 3A;

EID: 0038311984     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.31.7.945     Document Type: Article

References (40)

1. Backman JT, Aranko K, Himberg JJ, and Olkkola KT (1994) A pharmacokinetic interaction between roxithromycin and midazolam. Eur J Clin Pharmacol 46: 551-555.
2. Benet LZ, Die S, and Schwartz JB (1996) Design and optimization of dosage regimens; pharmacokinetic data, in Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed. (Hardman JG and Limbird LE, eds) pp 1707-1792, McGraw-Hill, New York.
3. Birkett DJ. Robson RA, Grgurinovich N, and Tonkin A (1990) Single oral dose pharmacokinetics of erythromycin and roxithromycin and the effects of chronic dosing. Ther Drug Monit 12:65-71.
4. Chu SY, Sennello LT, Bunnell ST, Varga LL, Wilson DS, and Sonders RC (1992) Pharmaco-kinetics of clarithromycin, a new macrolide, after single ascending oral doses. Antimicrob Agents Chemother 36:2447-2453.
5. Echizen H, Kawasaki H, Chiba K, Tani M, and Ishizaki T (1993) A potent inhibitory effect of erythromycin and other macrolide antibiotics on the mono-N-dealkylation metabolism of disopyramide with human liver microsomes. J Pharmacol Exp Ther 264:1425-1431.
6. Food and Drug Administration (1990) Transcript of Proceedings. Pulmonary-Allergy Drugs Advisory Committee, June 11, 1990. Department of Health and Human Services, Public Health Service, Rockville, MD.
7. Foulds G, Shepard RM, and Johnson RB (1990) The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 25 (Suppl):73-82.
8. Gascon MP and Dayer P (1991) In vitro forecasting of drugs which may interfere with the biotransformation of midazolam. Eur J Clin Pharmacol 41:573-578.
9. Gorski JC, Hall SD, Jones DR, VandenBranden M, and Wrighton SA (1994) Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 47:1643-1653.
10. Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM Jr, and Hall SD (1998) The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 64:133-143.
11. Honig PK, Wortham DC, Zamani K, and Cantilena LR (1994) Comparison of the effect of the macrolide antibiotics erythromycin, clarithromycin and azithromycin on terfenadine steady-state pharmacokinetics and electrocardiographic parameters. Drug Investig 7:148-156.
12. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, and Sugiyama Y (1998) Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 50:387-411.
13. Iwatsubo T, Hirota N, Ooie T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA, and Sugiyama Y (1997) Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 73:147-171.
14. Jurima-Romet M, Crawford K, Cyr T, and Inaba T (1994) Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metab Dispos 22:849-857.
15. Kanamitsu S, Ito K, Green CE, Tyson CA, Shimada N, and Sugiyama Y (2000b) Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4. Pharm Res (NY) 17:419-426.
16. Kanamitsu S, Ito K, Okuda H, Ogura K, Watabe T, Muro K, and Sugiyama Y (2000a) Prediction of in vivo drug-drug interactions based on mechanism-based inhibition from in vitro data: inhibition of 5-fluorouracil metabolism by (E)-5-(2-Bromovinyl)uracil. Drug Metab Dispos 28:467-474.
17. Lown KS, Thummel KE, Benedict PE, Shen DD, Turgeon DK, Berent S, and Watkins PB (1995) The erythromycin breath test predicts the clearance of midazolam. Clin Pharmacol Ther 57:16-24.
18. Mayhew BS, Jones DR, and Hall SD (2000) An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab Dispos 28:1031-1037.
19. Murray M (1987) Mechanisms of the inhibition of cytochrome P-450 -mediated drug oxidation by therapeutic agents. Drug Metab Rev 18:55-81.
20. Olkkola KT, Aranko K. Luurila H, Hiller A, Saamivaara L, Himberg JJ, and Neuvonen PJ (1993) A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 53:298-305.
21. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, and Thummel KE (1997) Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 283:1552-1562.
22. Periti P, Mazzei T, Mini E, and Novelli A (1992) Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 23:106-131.
23. Shiraki H and Guengerich FP (1984) Turnover of membrane proteins: kinetics of induction and degradation of seven forms of rat liver microsomal cytochrome P-450, NADPH-cytochrome P450 reductase and epoxide hydrolase. Arch Biochem Biophys 235:86-96.
24. Silverman RB (1988) Mechanism-based enzyme inactivation, in Chemistry and Enzymology, vol 1, pp 3-30, CRC Press LLC, Boca Raton, FL.
25. Smith JW. Dyke RW, and Griffith RS (1953) Absorption following oral administration of erythromycin. J Am Med Assoc 151:805-810.
26. Smith MT, Eadie MJ, and Brophy TO (1981) The pharmacokinetics of midazolam in man. Eur J Clin Pharmacol 19:271-278.
27. Suwa T, Urano H, Kodama T, Nakamura M, and Watanabe T (1988) Metabolic fate of TE-031 (A-56268) (8) absorption and excretion in humans (bioassay). Chemotherapy 36:921-932.
28. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, and Wilkinson GR (1996) Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 59:491-502.
29. Thummel KE and Wilkinson GR (1998) In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 38:389-460.
30. Tinel M, Descatoire V, Larrey D, Loeper J, Labbe G, Letteron P. and Pessayre D (1989) Effects of clarithromycin on cytochrome P-450. Comparison with other macrolides. J Pharmacol Exp Ther 250:746-751.
31. von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, Pritchard GA, Wright CE, and Shader RI (1996) Triazolam biotransformation by human liver microsomes in vitro: effect of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 276:370-379.
32. Waley SG (1985) Kinetics of suicide substrates. Practical procedures for determining parameters. Biochem J 227:843-849.
33. Westphal JF (2000) Macrolide-induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. Br J Clin Pharmacol 50:285-295.
34. Wrighton SA and Ring BJ (1994) Inhibition of human CYP3A catalyzed 1′-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine and nizatidine. Pharm Res (NY) 11:921-924.
35. Yago K, Kuroyama M, Motohashi S, and Kumano K (1996) Protein binding of clarithromycin in patients with chronic renal failure (in Japanese). Jpn J Antibiot 49:256-263.
36. Yamano K, Yamamoto K, Katashima M, Kotaki H, Takedomi S, Matsuo H, Ohtani H, Sawada Y, and Iga T (2001) Prediction of midazolam - CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution and metabolism data. Drug Metab Dispos 29:443-452.
37. Yamaoka K, Tanigawara Y, Nakagawa T, and Uno T (1981) A pharmacokinetic analysis program (MULTI) for microcomputer. J Pharmacobio-Dyn 4:879-885.
38. Yamazaki H and Shimada T (1998) Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin and erythromycin. Drug Metab Dispos 26:1053-1057.
39. Yeates RA, Laufen H, and Zimmermann T (1996) Interaction between midazolam and clarithromycin: comparison with azithromycin. Int J Clin Pharm Ther 34:400-405.
40. Zimmermann T, Yeates RA, Laufen H, Scharpf F, Leitold M, and Wildfeuer A (1996) Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam. Arzneim-Forsch 46:213-217.